PRKAA1 and prostate cancer: Collectively, these data suggest that auraptene suppresses prostate cancer proliferation and AR activity by inducing AMPK activation, which is mediated by an increase in the cellular ADP/ATP ratio and subsequent phosphorylation by LKB1.